Impacto das comorbilidades num programa de reabilitação respiratória em doentes com doença pulmonar obstrutiva crónica

Carreiro, Alexandra; Santos, J Flores Alves Dos; Rodrigues, Fátima

doi:10.1016/j.rppneu.2012.12.004

Cited by 32 publications

(17 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The flow chart of the results of the search strategies and the study selection are shown in Figure 1. Comorbidities were either retrieved from the medical record of the patients [16, 17] or were identified based on the Charlson Comorbidity Index [16, 18–20]. All articles reported comorbidities to be prevalent among patients with COPD, with a mean percentage of 70% of patients having one or more comorbidities.…”

Section: Resultsmentioning

confidence: 99%

“…Pulmonary rehabilitation programs were supervised and involved either strength training or both strength and whole body exercise training. In 2 out of 4 articles, pulmonary rehabilitation programs were multidisciplinary [17, 18]. One article reported patients to be referred to standard outpatient rehabilitation, with no detailed description of the program [20].…”

Section: Resultsmentioning

confidence: 99%

“… Table 3 provides an overview of the obtained odds ratios (95% CIs) of the logistic regression analyses. More specifically, we concluded that patients with COPD and anxiety and/or depression have a 10 times higher chance of not reaching the minimal clinically important difference (MCID) in symptoms of dyspnea [17]. On the other hand, Crisafulli et al [16] showed that having metabolic disease is associated with a higher chance of improving the symptoms of dyspnea and that osteoporosis is associated with a lower chance of improving the symptoms of dyspnea.…”

Section: Resultsmentioning

confidence: 99%

“…Improvements in functional exercise capacity were 4 times lower in patients with osteoporosis [18] and 2 times higher in patients with cardiovascular disease [16]. There was no consistency regarding the association between metabolic disease and functional exercise capacity, since 3 studies showed different results [16, 17, 20]. Patients with cardiovascular and metabolic disease will improve less in terms of quality of life [16, 17].…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

The Influence of Comorbidities on Outcomes of Pulmonary Rehabilitation Programs in Patients with COPD: A Systematic Review

Hornikx

Remoortel

Demeyer

et al. 2013

BioMed Research International

View full text Add to dashboard Cite

Introduction. Chronic obstructive pulmonary disease (COPD) is associated with comorbidities such as cardiovascular disease, metabolic disease, osteoporosis, and anxiety and/or depression. Although pulmonary rehabilitation programs are proven to be beneficial in patients with COPD, it is unclear whether comorbidities influence pulmonary rehabilitation outcomes. The aim of the present review was to investigate to what extent the presence of comorbidities can affect pulmonary rehabilitation outcomes. Methods. The systematic literature search (Pubmed, EMBASE, and PEDro) resulted in 4 articles meeting the inclusion criteria. The odds ratios (95% confidence intervals) of the logistic regression analyses, with comorbidities as independent variables and pulmonary rehabilitation outcomes (dyspnea, functional exercise capacity, and quality of life) as dependent variables, were used for data extraction. Results. Patients with anxiety and/or depression less likely improve in dyspnea. Osteoporosis is associated with less improvements in functional exercise capacity, while cardiovascular disease does not seem to negatively impact on this outcome. Patients with cardiovascular comorbidity will experience less positive changes in quality of life. Conclusion. Evidence from literature suggests that comorbidities can have a negative influence on pulmonary rehabilitation outcomes. Screening for comorbidities in pulmonary rehabilitation settings seems useful to readdress the right patients for individually tailored pulmonary rehabilitation.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

The Influence of Comorbidities on Outcomes of Pulmonary Rehabilitation Programs in Patients with COPD: A Systematic Review

Hornikx

Remoortel

Demeyer

et al. 2013

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…Patients with COPD have several comorbidities and are likely to be on other medications 29. Also, physical decon-ditioning due to hyperinflation and cognitive impairment would make the use of multiple inhalers difficult for these patients 10.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study

Dahl¹,

Jadayel²,

Alagappan³

et al. 2013

COPD

View full text Add to dashboard Cite

IntroductionThe BEACON study evaluated the efficacy and safety of QVA149, a once-daily dual bronchodilator containing a fixed-dose combination of the long-acting β2-agonist (LABA) indacaterol and long-acting muscarinic antagonist (LAMA) glycopyrronium (NVA237), in development for the treatment of patients with chronic obstructive pulmonary disease (COPD), compared with the free-dose concurrent administration of indacaterol plus glycopyrronium (IND+GLY).MethodsIn this multicenter, double-blind, parallel group study, patients with stage II or stage III COPD (Global initiative for chronic Obstructive Lung Disease [GOLD] 2010) were randomized (1:1) to once-daily QVA149 (110 μg indacaterol/50 μg glycopyrronium) or concurrent administration of indacaterol (150 μg) and glycopyrronium (50 μg) via the Breezhaler® device (Novartis AG, Basel, Switzerland) for 4 weeks. The primary endpoint was to evaluate the noninferiority of QVA149 as compared with concurrent administration of IND+GLY, for trough forced expiratory volume in 1 second (FEV1) after 4 weeks of treatment. The other assessments included FEV1 area under the curve from 0 to 4 hours (AUC0–4 hours) at day 1 and week 4, symptom scores, rescue medication use, safety, and tolerability over the 4-week study period.ResultsOf 193 patients randomized, 187 (96.9%) completed the study. Trough FEV1 at week 4 for QVA149 and IND+GLY was 1.46 L ± 0.02 and 1.46 L ± 0.18, respectively. The FEV1 AUC0–4 hours at day 1 and week 4 were similar between the two treatment groups. Both treatment groups had a similar reduction in symptom scores and rescue medication use for the 4-week treatment period. Overall, 25.6% of patients in QVA149 group and 25.2% in the IND+GLY group experienced an adverse event, with the majority being mild-to-moderate in severity. No deaths were reported during the study or during the 30 days follow-up period.ConclusionThe BEACON study demonstrated that once-daily QVA149 provides an efficacy and safety profile similar to the concurrent administration of its monocomponents indacaterol and glycopyrronium.

show abstract

Targeted interventions and approaches to care for people living with chronic obstructive pulmonary disease and at least one other long-term condition: a mixed methods review

Janjua

McDonnell

Harrison

et al. 2019

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

show abstract

Impacto das comorbilidades num programa de reabilitação respiratória em doentes com doença pulmonar obstrutiva crónica

Cited by 32 publications

References 36 publications

The Influence of Comorbidities on Outcomes of Pulmonary Rehabilitation Programs in Patients with COPD: A Systematic Review

The Influence of Comorbidities on Outcomes of Pulmonary Rehabilitation Programs in Patients with COPD: A Systematic Review

Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study

Targeted interventions and approaches to care for people living with chronic obstructive pulmonary disease and at least one other long-term condition: a mixed methods review

Contact Info

Product

Resources

About